Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
8.10
+0.01 (0.12%)
At close: Apr 24, 2025, 4:00 PM
7.96
-0.14 (-1.73%)
Pre-market: Apr 25, 2025, 4:37 AM EDT
Company Description
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs.
It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases.
It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc.
| Country | Canada |
| Founded | 1993 |
| IPO Date | Jan 26, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Peter Greenleaf |
Contact Details
Address: #140, 14315 – 118 Avenue Edmonton, AB T5L 4S6 Canada | |
| Phone | 250 744 2487 |
| Website | auriniapharma.com |
Stock Details
| Ticker Symbol | AUPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001600620 |
| CUSIP Number | 05156V102 |
| ISIN Number | CA05156V1022 |
| Employer ID | 98-1231763 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter S. Greenleaf M.B.A. | Chief Executive Officer and Director |
| Joseph M. Miller CPA | Chief Financial Officer |
| Matthew Maxwell Donley M.B.A. | Chief Operations Officer |
| Stephen P. Robertson | Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer |
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer |
| Andrea Levin Christopher | Executive Director of Corporate Communications and Investor Relations |
| Dr. Premchandran Ramiya Ph.D. | Senior Vice President of Manufacturing and Supply Chain |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 4, 2025 | SCHEDULE 13D/A | Filing |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Sep 12, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 12, 2024 | 8-K | Current Report |